Lets take a closer look at GHK-Cu and how it works: GHK peptide bound to copper was first discovered by Loren Pickart in the 70s
As of 2026, no peer-reviewed human clinical trials on FOXO4-DRI have been published
FDA's own scientists recommended against it, citing inadequate physicochemical characterization, immunogenicity risk from aggregation and peptide-related impurities, and insufficient evidence of effectiveness
Thus, a higher Bcl-2/Bax ratio is posted as a predominance of Bcl-2, which may inhibit apoptosis and apparently promotes cell survival
Cysteine Compound Summary CID (5862) Khawar SL, Watson K, Jones GL
It's like watering plants: regular, constant attention does better than periodic lushness and nothing for a week